Avid bioservices reports financial results for third quarter ended january 31, 2024

-- recorded third quarter revenue of $33.8 million -- -- signed $41 million in net new business resulting in record high backlog of $206 million --
CDMO Ratings Summary
CDMO Quant Ranking